ProstaLund CoreTherm BPH Device Arrives In U.S., Distributed Through ACMI
This article was originally published in The Gray Sheet
Executive Summary
ProstaLund will immediately fill $2.3 mil. in back-orders for its CoreTherm microwave transurethral benign prostatic hyperplasia (BPH) treatment device, approved via PMA in December
You may also be interested in...
Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy
Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology
Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy
Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology
Urologix v. ProstaLund
Motion for preliminary injunction against sales of ProstaLund's CoreTherm microwave thermotherapy system for benign prostatic hyperplasia is denied by Milwaukee federal court Judge Lynn Adelman, clearing the way for U.S. marketing, pending PMA approval "in the near future," ProstaLund says. Adelman also rules that one of two Urologix patents asserted against ProstaLund is invalid. ACMI will distribute the device...